Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Investigational Site Number : 0560003, Edegem

Investigational Site Number : 0560001, Leuven

Investigational Site Number : 0560002, Liège

Investigational Site Number : 2500007, Marseille

Roswell Park Cancer Institute Site Number : 8400004, Buffalo

Investigational Site Number : 3800001, Rozzano

Investigational Site Number : 3800002, Milan

Investigational Site Number : 7240009, Madrid / Madrid

Investigational Site Number : 7240002, Madrid

Investigational Site Number : 7240008, Majadahonda

Investigational Site Number : 7240003, Málaga

Investigational Site Number : 2500003, Bordeaux

Investigational Site Number : 3800004, Aviano (PN)

Investigational Site Number : 2500005, Montpellier

Investigational Site Number : 7920003, Istanbul

Investigational Site Number : 7920004, Istanbul

Investigational Site Number : 2500002, Rennes

Investigational Site Number : 7240005, Seville

Investigational Site Number : 2500006, Saint-Herblain

Investigational Site Number : 7240007, Valencia

Investigational Site Number : 3800003, Ravenna

Renovatio Clinical Site Number : 8400003, El Paso

Investigational Site Number : 2500001, Créteil

Investigational Site Number : 2500008, Saint-Mandé

Investigational Site Number : 2500009, Villejuif

Investigational Site Number : 3920002, Nagoya

Investigational Site Number : 3920001, Sapporo

Investigational Site Number : 3920005, Hirakata-shi

Investigational Site Number : 3920003, Sunto Gun

Investigational Site Number : 7240004, Barcelona

Investigational Site Number : 7240006, Barcelona

Investigational Site Number : 7240001, L'Hospitalet de Llobregat

Investigational Site Number : 7920002, Adana

Investigational Site Number : 7920005, Ankara

Investigational Site Number : 7920001, Malatya